HRP20210400T4 - Novi polimerni hgh predlijekovi - Google Patents
Novi polimerni hgh predlijekovi Download PDFInfo
- Publication number
- HRP20210400T4 HRP20210400T4 HRP20210400TT HRP20210400T HRP20210400T4 HR P20210400 T4 HRP20210400 T4 HR P20210400T4 HR P20210400T T HRP20210400T T HR P20210400TT HR P20210400 T HRP20210400 T HR P20210400T HR P20210400 T4 HRP20210400 T4 HR P20210400T4
- Authority
- HR
- Croatia
- Prior art keywords
- mass
- pharmaceutical formulation
- compound
- formula
- succinic acid
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 12
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims 6
- 239000001384 succinic acid Substances 0.000 claims 6
- 229940074409 trehalose dihydrate Drugs 0.000 claims 6
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 3
- 239000007983 Tris buffer Substances 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 239000012669 liquid formulation Substances 0.000 claims 3
- 229930182817 methionine Natural products 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 3
- 206010041092 Small for dates baby Diseases 0.000 claims 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 206010053759 Growth retardation Diseases 0.000 claims 1
- 108700005087 Homeobox Genes Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029748 Noonan syndrome Diseases 0.000 claims 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims 1
- 208000020221 Short stature Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G17/00—Cultivation of hops, vines, fruit trees, or like trees
- A01G17/005—Cultivation methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G2/00—Vegetative propagation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G7/00—Botany in general
- A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
- C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
- C08G2650/06—Epoxy-capping
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biodiversity & Conservation Biology (AREA)
- Ecology (AREA)
- Forests & Forestry (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (14)
1. Spoj, naznačen time, da je predstavljen formulom (IV):
[image]
u kojoj
D je hGH polipeptid od SEQ ID NO: 1, koji je vezan s ostatkom molekule kroz funkcionalnu aminoskupinu koja se pripravlja putem bočnog lanca lizina; i
svaki od p1, p2, p3, p4 je neovisno cijeli broj u rasponu od 210 do 240.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je svaki od p1, p2, p3, p4 neovisno cijeli broj u rasponu od 220 do 240.
3. Farmaceutska formulacija, naznačena time, da sadrži spoj prema patentnom zahtjevu 1 ili 2 i najmanje jednu pomoćnu tvar.
4. Farmaceutska formulacija prema patentnom zahtjevu 3, naznačena time, da je farmaceutska formulacija tekuća formulacija koja sadrži:
spoj formule (IV) 15-120 mg/ml
sukcinsku kiselinu 5-40 mM
opcionalno trehalozu dihidrat 60-86 mg/ml
opcionalno metionin 5-40 mM
s time, da posjeduje pH vrijednost u rasponu od pH 4,0 do pH 6,0, te koja se titrira uporabom prikladnog pufera.
5. Farmaceutska formulacija prema patentnom zahtjevu 3 ili 4, naznačena time, da je farmaceutska formulacija tekuća formulacija koja sadrži:
spoj formule (IV) 30-45 mg/ml
sukcinsku kiselinu 5-20 mM
opcionalno trehalozu dihidrat 75-86 mg/ml
opcionalno metionin 5-20 mM
s time, da posjeduje pH vrijednost u rasponu od pH 4,0 do pH 6,0, te koja se titrira uporabom prikladnog pufera.
6. Farmaceutska formulacija prema patentnom zahtjevu 3 ili 4, naznačena time, da je farmaceutska formulacija tekuća formulacija koja sadrži:
spoj formule (IV) 75-105 mg/ml
sukcinsku kiselinu 5-20 mM
opcionalno trehalozu dihidrat 60-81 mg/ml
opcionalno metionin 5-20 mM
s time, da posjeduje pH vrijednost u rasponu od pH 4,0 do pH 6,0, te koja se titrira uporabom prikladnog pufera.
7. Farmaceutska formulacija prema patentnom zahtjevu 3, naznačena time, da je farmaceutska formulacija suha formulacija koja sadrži:
spoj formule (IV) 15-63 % (masa/masa)
sukcinsku kiselinu 0,6-2,5 % (masa/masa)
trehalozu dihidrat 32-84 % (masa/masa)
Tris 0,6-2,6 % (masa/masa).
8. Farmaceutska formulacija prema patentnom zahtjevu 3 ili 7, naznačena time, da je farmaceutska formulacija suha formulacija koja sadrži:
spoj formule (IV) 26-36 % (masa/masa)
sukcinsku kiselinu 0,5-1,9 % (masa/masa)
trehalozu dihidrat 60-73 % (masa/masa)
Tris 0,5-1,9 % (masa/masa).
9. Farmaceutska formulacija prema patentnom zahtjevu 3 ili 7, naznačena time, da je farmaceutska formulacija suha formulacija koja sadrži:
spoj formule (IV) 48-62 % (masa/masa)
sukcinsku kiselinu 0,4-1,4 % (masa/masa)
trehalozu dihidrat 35-52 % (masa/masa)
Tris 0,4-1,4 % (masa/masa).
10. Spoj prema patentnom zahtjevu 1 ili 2, ili farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 3 do 9, naznačen/a time, da se upotrebljava kao lijek.
11. Spoj prema patentnom zahtjevu 1 ili 2, ili farmaceutska formulacija prema bilo kojem od patentnih zahtjeva 3 do 9, naznačen/a time, da je za uporabu u postupku liječenja bolesti odabrane iz skupine koja se sastoji od sljedećih: nedostatak hormona rasta kod djece, idiopatski niski rast, homeobox-genske mutacije za niski rast, Turnerov sindrom, Noonanov sindrom, Prader-Willi sindrom, djeca rođena premalena za gestacijsku dob, kronična bubrežna insuficijencija, nedostatak hormona rasta kod odraslih, iscrpljenost uslijed HIV-a ili AIDS-a ili ostalih malignosti, sindrom kratkih crijeva, sarkopenija i krhkost.
12. Spoj ili farmaceutska formulacija za uporabu prema patentnom zahtjevu 11, naznačeni time, da se kod bolesti radi o nedostatku hormona rasta kod djece.
13. Spoj ili farmaceutska formulacija za uporabu prema patentnom zahtjevu 11, naznačeni time, da se kod bolesti radi o nedostatku hormona rasta kod odraslih.
14. Spoj ili farmaceutska formulacija za uporabu prema patentnom zahtjevu 11, naznačeni time, da se kod bolesti radi o djeci koja su rođena premalena za gestacijsku dob.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14193603 | 2014-11-18 | ||
| EP19214864.1A EP3653227B9 (en) | 2014-11-18 | 2015-11-17 | Novel polymeric hgh prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20210400T1 HRP20210400T1 (hr) | 2021-04-16 |
| HRP20210400T4 true HRP20210400T4 (hr) | 2022-04-29 |
Family
ID=51951624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210400TT HRP20210400T4 (hr) | 2014-11-18 | 2015-11-17 | Novi polimerni hgh predlijekovi |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10799563B2 (hr) |
| EP (3) | EP3653227B9 (hr) |
| JP (5) | JP6783782B2 (hr) |
| KR (2) | KR102608645B1 (hr) |
| AU (3) | AU2015348633C1 (hr) |
| BR (1) | BR112017009798A8 (hr) |
| CA (1) | CA2968282A1 (hr) |
| CY (1) | CY1123963T1 (hr) |
| DK (2) | DK3653227T5 (hr) |
| ES (2) | ES2864415T7 (hr) |
| FI (2) | FI3237014T3 (hr) |
| FR (1) | FR22C1029I2 (hr) |
| HR (1) | HRP20210400T4 (hr) |
| HU (2) | HUE053855T2 (hr) |
| IL (2) | IL307773A (hr) |
| LT (2) | LT3653227T (hr) |
| MX (2) | MX2017006113A (hr) |
| NL (1) | NL301172I2 (hr) |
| NO (1) | NO2022014I1 (hr) |
| PL (1) | PL3653227T6 (hr) |
| PT (1) | PT3653227T (hr) |
| RS (1) | RS61734B2 (hr) |
| RU (1) | RU2718664C2 (hr) |
| SG (2) | SG10202105511RA (hr) |
| SI (1) | SI3653227T1 (hr) |
| WO (1) | WO2016079114A1 (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3220892B1 (en) | 2014-11-21 | 2021-10-13 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
| KR102531327B1 (ko) | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
| US20210008168A1 (en) | 2018-03-28 | 2021-01-14 | Ascendis Pharma A/S | Conjugates |
| SG11202007524QA (en) * | 2018-03-28 | 2020-09-29 | Ascendis Pharma Oncology Div A/S | Il-2 conjugates |
| KR20210113272A (ko) | 2019-01-04 | 2021-09-15 | 아센디스 파마 온콜로지 디비전 에이/에스 | 선천 면역 작용제를 위한 지속되는 국소 약물 수준 |
| WO2020141225A1 (en) | 2019-01-04 | 2020-07-09 | Ascendis Pharma A/S | Minimization of systemic inflammation |
| TW202042844A (zh) | 2019-01-04 | 2020-12-01 | 丹麥商阿仙帝斯製藥公司 | 模式辨別受體(pattern recognition receptor)促效劑的共軛物 |
| EP3906018A1 (en) | 2019-01-04 | 2021-11-10 | Ascendis Pharma Oncology Division A/S | Induction of sustained local inflammation |
| CA3131817A1 (en) * | 2019-03-04 | 2020-09-10 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| AU2021286177A1 (en) | 2020-06-03 | 2022-12-01 | Ascendis Pharma Oncology Division A/S | IL-2 sequences and uses thereof |
| AU2022246997A1 (en) | 2021-04-01 | 2023-09-28 | Ascendis Pharma A/S | Use of long-acting growth hormone for treating inflammation-induced diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011197A (en) * | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
| EP1625855A1 (en) * | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Polymeric prodrug with a self-immolative linker |
| EP1579873A1 (en) * | 2004-03-23 | 2005-09-28 | Complex Biosystems GmbH | Polymeric prodrugs |
| ES2741524T3 (es) * | 2004-03-23 | 2020-02-11 | Ascendis Pharma Gmbh | Profármaco polimérico con un enlazador autoinmolador |
| EP1861125A2 (en) * | 2005-03-23 | 2007-12-05 | Nektar Therapeutics Al, Corporation | Conjugates of an hgh moiety and peg derivatives |
| ES2587400T3 (es) * | 2008-04-29 | 2016-10-24 | Ascendis Pharma Growth Disorders Division A/S | Compuestos de hormona de crecimiento humana recombinante pegilada |
| EP2113256A1 (en) * | 2008-04-29 | 2009-11-04 | Ascendis Pharma AS | PEGylated rhGH compounds |
| CN102711733A (zh) * | 2009-12-15 | 2012-10-03 | 阿森迪斯药物股份有限公司 | 瞬时连接于聚合物载体的干生长激素组合物 |
| CA3131817A1 (en) * | 2019-03-04 | 2020-09-10 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
-
2015
- 2015-11-17 KR KR1020177016287A patent/KR102608645B1/ko active IP Right Grant
- 2015-11-17 RU RU2017121203A patent/RU2718664C2/ru active
- 2015-11-17 EP EP19214864.1A patent/EP3653227B9/en active Active
- 2015-11-17 US US15/527,744 patent/US10799563B2/en active Active
- 2015-11-17 IL IL307773A patent/IL307773A/en unknown
- 2015-11-17 JP JP2017544993A patent/JP6783782B2/ja active Active
- 2015-11-17 FI FIEP15797642.4T patent/FI3237014T3/fi active
- 2015-11-17 ES ES19214864T patent/ES2864415T7/es active Active
- 2015-11-17 BR BR112017009798A patent/BR112017009798A8/pt active Search and Examination
- 2015-11-17 SG SG10202105511RA patent/SG10202105511RA/en unknown
- 2015-11-17 WO PCT/EP2015/076813 patent/WO2016079114A1/en active Application Filing
- 2015-11-17 IL IL251906A patent/IL251906B2/en unknown
- 2015-11-17 DK DK19214864.1T patent/DK3653227T5/da active
- 2015-11-17 CA CA2968282A patent/CA2968282A1/en active Pending
- 2015-11-17 RS RS20210444A patent/RS61734B2/sr unknown
- 2015-11-17 MX MX2017006113A patent/MX2017006113A/es unknown
- 2015-11-17 DK DK15797642.4T patent/DK3237014T3/da active
- 2015-11-17 EP EP23164305.7A patent/EP4218823A3/en active Pending
- 2015-11-17 SG SG11201703870UA patent/SG11201703870UA/en unknown
- 2015-11-17 PT PT192148641T patent/PT3653227T/pt unknown
- 2015-11-17 KR KR1020237037045A patent/KR20230152187A/ko not_active Application Discontinuation
- 2015-11-17 ES ES15797642T patent/ES2947818T3/es active Active
- 2015-11-17 PL PL19214864T patent/PL3653227T6/pl unknown
- 2015-11-17 SI SI201531543T patent/SI3653227T1/sl unknown
- 2015-11-17 AU AU2015348633A patent/AU2015348633C1/en active Active
- 2015-11-17 LT LTEP19214864.1T patent/LT3653227T/lt unknown
- 2015-11-17 EP EP15797642.4A patent/EP3237014B1/en active Active
- 2015-11-17 HR HRP20210400TT patent/HRP20210400T4/hr unknown
- 2015-11-17 HU HUE19214864A patent/HUE053855T2/hu unknown
-
2017
- 2017-05-10 MX MX2022009155A patent/MX2022009155A/es unknown
-
2020
- 2020-08-28 US US17/006,589 patent/US20200390864A1/en active Pending
- 2020-10-22 JP JP2020177083A patent/JP6982156B2/ja active Active
- 2020-11-18 AU AU2020270494A patent/AU2020270494B2/en active Active
-
2021
- 2021-03-18 CY CY20211100235T patent/CY1123963T1/el unknown
- 2021-11-18 JP JP2021187453A patent/JP7210683B2/ja active Active
-
2022
- 2022-04-20 NL NL301172C patent/NL301172I2/nl unknown
- 2022-05-10 HU HUS2200019C patent/HUS2200019I1/hu unknown
- 2022-05-12 NO NO2022014C patent/NO2022014I1/no unknown
- 2022-05-23 LT LTPA2022506C patent/LTPA2022506I1/lt unknown
- 2022-06-03 FI FIC20220017C patent/FIC20220017I1/fi unknown
- 2022-06-10 FR FR22C1029C patent/FR22C1029I2/fr active Active
-
2023
- 2023-01-11 JP JP2023002061A patent/JP7431355B2/ja active Active
-
2024
- 2024-02-01 JP JP2024013884A patent/JP2024054177A/ja active Pending
- 2024-02-23 AU AU2024201227A patent/AU2024201227A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210400T4 (hr) | Novi polimerni hgh predlijekovi | |
| HRP20180425T1 (hr) | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| PH12017500844B1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| SI2648520T1 (en) | Formulation of dexmedetomidine pre-mixtures | |
| JP2015527402A5 (hr) | ||
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| EA201492021A1 (ru) | Антительный состав | |
| HRP20150353T1 (hr) | Farmaceutski pripravak koji sadrži glp-1 agonist, inzulin i metionin | |
| BR112012030177A2 (pt) | composto, uso do mesmo, e, composição farmacêutica | |
| JP2015517488A5 (hr) | ||
| BR112014009225A8 (pt) | uso de micelas de proteína de soro de leite para crianças pequenas em risco de obesidade ou diabetes | |
| HRP20211046T1 (hr) | Upotreba derivata benzimidazola kod noćnog proboja kiseline | |
| JP2011026348A5 (hr) | ||
| HRP20230470T1 (hr) | Formulacija fiksnog omjera inzulin glargin/liksisenatid | |
| HRP20200691T1 (hr) | Pedijatrijska formulacija | |
| RU2017112303A (ru) | Способ применения комбинации нового производного гидроксамовой кислоты и антибактериального вещества | |
| ES2883639T3 (es) | Nuevo inhibidor de MEK para el tratamiento de infecciones víricas y bacterianas | |
| JP2011068692A5 (hr) | ||
| JP2016534062A5 (hr) | ||
| Ma et al. | Trace metal elements: a bridge between host and intestinal microorganisms | |
| JP2022529343A (ja) | ウイルス感染および細菌感染の治療のための新規ｍｅｋ阻害剤 | |
| JP2015524808A5 (hr) | ||
| BR112017015338A2 (pt) | composição de clorofilina e método para tratamento | |
| RU2017107254A (ru) | Модифицированный молозивный белок и его применение |